SK4042003A3 - Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them - Google Patents

Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them Download PDF

Info

Publication number: SK4042003A3
Authority: SK; Slovakia
Prior art keywords: alkyl; melatonin; disorders; compounds; aryl
Prior art date: 2000-10-03

Application number

SK404-2003A

Other languages

English (en)

Slovak (sk)

Inventor

Nava Zisapel

Moshe Laudon

Original Assignee

Neurim Pharma 1991

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-03

Filing date

2001-09-25

Publication date

2003-09-11

2001-09-25 Application filed by Neurim Pharma 1991 filed Critical Neurim Pharma 1991

2003-09-11 Publication of SK4042003A3 publication Critical patent/SK4042003A3/sk

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 45
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 9
APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical class C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 title description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 19
239000000203 mixture Substances 0.000 claims abstract description 19
208000035475 disorder Diseases 0.000 claims abstract description 11
208000020016 psychiatric disease Diseases 0.000 claims abstract description 9
150000003839 salts Chemical class 0.000 claims abstract description 9
210000003169 central nervous system Anatomy 0.000 claims abstract description 8
208000015114 central nervous system disease Diseases 0.000 claims abstract description 6
239000003814 drug Substances 0.000 claims abstract description 5
125000000217 alkyl group Chemical group 0.000 claims description 18
230000000694 effects Effects 0.000 claims description 13
206010028980 Neoplasm Diseases 0.000 claims description 12
238000011282 treatment Methods 0.000 claims description 12
239000002904 solvent Substances 0.000 claims description 9
241001465754 Metazoa Species 0.000 claims description 8
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
-1 2,4-dinitro-5-aminophenyl Chemical group 0.000 claims description 7
230000032683 aging Effects 0.000 claims description 7
125000003118 aryl group Chemical group 0.000 claims description 7
206010019233 Headaches Diseases 0.000 claims description 6
208000019695 Migraine disease Diseases 0.000 claims description 6
230000002124 endocrine Effects 0.000 claims description 6
231100000869 headache Toxicity 0.000 claims description 6
125000001041 indolyl group Chemical group 0.000 claims description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
210000002307 prostate Anatomy 0.000 claims description 6
208000024172 Cardiovascular disease Diseases 0.000 claims description 5
238000009472 formulation Methods 0.000 claims description 5
210000000987 immune system Anatomy 0.000 claims description 5
201000001881 impotence Diseases 0.000 claims description 5
206010027599 migraine Diseases 0.000 claims description 5
239000003755 preservative agent Substances 0.000 claims description 5
125000003545 alkoxy group Chemical group 0.000 claims description 4
208000030533 eye disease Diseases 0.000 claims description 4
229910052736 halogen Inorganic materials 0.000 claims description 4
150000002367 halogens Chemical class 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
230000002265 prevention Effects 0.000 claims description 4
AWVTVFYFAAKGOE-UHFFFAOYSA-N 3-n-[2-(1h-indol-3-yl)ethyl]-4,6-dinitrobenzene-1,3-diamine Chemical compound C1=C([N+]([O-])=O)C(N)=CC(NCCC=2C3=CC=CC=C3NC=2)=C1[N+]([O-])=O AWVTVFYFAAKGOE-UHFFFAOYSA-N 0.000 claims description 3
241000124008 Mammalia Species 0.000 claims description 3
239000003963 antioxidant agent Substances 0.000 claims description 3
239000003995 emulsifying agent Substances 0.000 claims description 3
125000000623 heterocyclic group Chemical group 0.000 claims description 3
229910052739 hydrogen Inorganic materials 0.000 claims description 3
239000001257 hydrogen Substances 0.000 claims description 3
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
DVMBDPMSHUSHMM-UHFFFAOYSA-N n-[2-(1h-indol-3-yl)ethyl]-2,4-dinitroaniline Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC=C1NCCC1=CNC2=CC=CC=C12 DVMBDPMSHUSHMM-UHFFFAOYSA-N 0.000 claims description 3
FAVQUYHPGBZYDL-UHFFFAOYSA-N n-[2-(5-methyl-1h-indol-3-yl)ethyl]-2,4-dinitroaniline Chemical compound C12=CC(C)=CC=C2NC=C1CCNC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O FAVQUYHPGBZYDL-UHFFFAOYSA-N 0.000 claims description 3
229910052760 oxygen Inorganic materials 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
239000000825 pharmaceutical preparation Substances 0.000 claims description 3
230000002335 preservative effect Effects 0.000 claims description 3
239000000126 substance Substances 0.000 claims description 3
229910052717 sulfur Inorganic materials 0.000 claims description 3
230000000699 topical effect Effects 0.000 claims description 3
239000002253 acid Substances 0.000 claims description 2
230000003078 antioxidant effect Effects 0.000 claims description 2
230000027455 binding Effects 0.000 claims description 2
229910052799 carbon Inorganic materials 0.000 claims description 2
238000013270 controlled release Methods 0.000 claims description 2
238000000034 method Methods 0.000 claims description 2
150000002431 hydrogen Chemical class 0.000 claims 2
ATMPNDLPCHRMNR-ATNAJCNCSA-N (4S)-2,4-diamino-5-(5-methyl-1H-indol-3-yl)-3-oxo-N-phenylpentanamide Chemical compound CC1=CC=C2NC=C(C[C@H](N)C(=O)C(C(=O)NC3=CC=CC=C3)N)C2=C1 ATMPNDLPCHRMNR-ATNAJCNCSA-N 0.000 claims 1
241001354782 Nitor Species 0.000 claims 1
208000022873 Ocular disease Diseases 0.000 claims 1
239000002537 cosmetic Substances 0.000 claims 1
BJHIKXHVCXFQLS-UYFOZJQFSA-N keto-D-fructose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 claims 1
125000004999 nitroaryl group Chemical group 0.000 claims 1
208000017497 prostate disease Diseases 0.000 claims 1
230000007958 sleep Effects 0.000 abstract description 9
208000019888 Circadian rhythm sleep disease Diseases 0.000 abstract description 6
238000004519 manufacturing process Methods 0.000 abstract description 5
208000019116 sleep disease Diseases 0.000 abstract description 5
208000001456 Jet Lag Syndrome Diseases 0.000 abstract description 4
208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 abstract description 4
208000012672 seasonal affective disease Diseases 0.000 abstract description 4
230000003280 chronobiological effect Effects 0.000 abstract description 3
206010015037 epilepsy Diseases 0.000 abstract description 3
230000001193 melatoninergic effect Effects 0.000 abstract description 3
230000004770 neurodegeneration Effects 0.000 abstract description 3
208000015122 neurodegenerative disease Diseases 0.000 abstract description 3
208000011580 syndromic disease Diseases 0.000 abstract description 3
208000019901 Anxiety disease Diseases 0.000 abstract description 2
206010010904 Convulsion Diseases 0.000 abstract description 2
230000036506 anxiety Effects 0.000 abstract description 2
230000003111 delayed effect Effects 0.000 abstract description 2
230000001613 neoplastic effect Effects 0.000 abstract 1
230000009758 senescence Effects 0.000 abstract 1
229960003987 melatonin Drugs 0.000 description 81
DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 78
YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 74
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 22
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
210000004556 brain Anatomy 0.000 description 11
239000000243 solution Substances 0.000 description 11
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
239000000047 product Substances 0.000 description 10
239000000741 silica gel Substances 0.000 description 10
229910002027 silica gel Inorganic materials 0.000 description 10
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
210000004027 cell Anatomy 0.000 description 9
239000007858 starting material Substances 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
201000010099 disease Diseases 0.000 description 8
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 8
229930195712 glutamate Natural products 0.000 description 8
ODQMCTXUHFTMIE-UHFFFAOYSA-N n-[2-(5-methoxy-1h-indol-3-yl)ethyl]-2,4-dinitroaniline Chemical compound C12=CC(OC)=CC=C2NC=C1CCNC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O ODQMCTXUHFTMIE-UHFFFAOYSA-N 0.000 description 8
235000017557 sodium bicarbonate Nutrition 0.000 description 8
229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
241000282412 Homo Species 0.000 description 6
102000001419 Melatonin receptor Human genes 0.000 description 5
241000700159 Rattus Species 0.000 description 5
239000005557 antagonist Substances 0.000 description 5
239000000463 material Substances 0.000 description 5
239000012528 membrane Substances 0.000 description 5
210000001700 mitochondrial membrane Anatomy 0.000 description 5
230000033764 rhythmic process Effects 0.000 description 5
JTEJPPKMYBDEMY-UHFFFAOYSA-N 5-methoxytryptamine Chemical compound COC1=CC=C2NC=C(CCN)C2=C1 JTEJPPKMYBDEMY-UHFFFAOYSA-N 0.000 description 4
241000699800 Cricetinae Species 0.000 description 4
108050009605 Melatonin receptor Proteins 0.000 description 4
208000018737 Parkinson disease Diseases 0.000 description 4
201000011510 cancer Diseases 0.000 description 4
230000007423 decrease Effects 0.000 description 4
229960003638 dopamine Drugs 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 3
PYOUAIQXJALPKW-UHFFFAOYSA-N 2-(5-methyl-1H-indol-3-yl)ethanamine Chemical compound CC1=CC=C2NC=C(CCN)C2=C1 PYOUAIQXJALPKW-UHFFFAOYSA-N 0.000 description 3
RAGRTYREMCPEIV-UHFFFAOYSA-N 5-fluoro-2,4-dinitroaniline Chemical compound NC1=CC(F)=C([N+]([O-])=O)C=C1[N+]([O-])=O RAGRTYREMCPEIV-UHFFFAOYSA-N 0.000 description 3
208000024827 Alzheimer disease Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
150000001412 amines Chemical class 0.000 description 3
239000000872 buffer Substances 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
239000005556 hormone Substances 0.000 description 3
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
230000003993 interaction Effects 0.000 description 3
LZBXUWOTXPNTNQ-UHFFFAOYSA-N n-(5-fluoro-2,4-dinitrophenyl)acetamide Chemical compound CC(=O)NC1=CC(F)=C([N+]([O-])=O)C=C1[N+]([O-])=O LZBXUWOTXPNTNQ-UHFFFAOYSA-N 0.000 description 3
230000009870 specific binding Effects 0.000 description 3
FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
229940097276 5-methoxytryptamine Drugs 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical class CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
206010022998 Irritability Diseases 0.000 description 2
102000016267 Leptin Human genes 0.000 description 2
108010092277 Leptin Proteins 0.000 description 2
XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Natural products O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
241001494479 Pecora Species 0.000 description 2
206010036618 Premenstrual syndrome Diseases 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
230000009471 action Effects 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
238000004166 bioassay Methods 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
244000309464 bull Species 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000030833 cell death Effects 0.000 description 2
230000006378 damage Effects 0.000 description 2
201000001098 delayed sleep phase syndrome Diseases 0.000 description 2
208000033921 delayed sleep phase type circadian rhythm sleep disease Diseases 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
230000012010 growth Effects 0.000 description 2
210000002216 heart Anatomy 0.000 description 2
230000000971 hippocampal effect Effects 0.000 description 2
208000026278 immune system disease Diseases 0.000 description 2
238000007689 inspection Methods 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
230000000302 ischemic effect Effects 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
229940039781 leptin Drugs 0.000 description 2
210000005036 nerve Anatomy 0.000 description 2
239000002674 ointment Substances 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
230000001817 pituitary effect Effects 0.000 description 2
230000002028 premature Effects 0.000 description 2
150000003254 radicals Chemical class 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000001932 seasonal effect Effects 0.000 description 2
230000028327 secretion Effects 0.000 description 2
230000003860 sleep quality Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
210000001835 viscera Anatomy 0.000 description 2
230000002618 waking effect Effects 0.000 description 2
METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
WGAXJEXVOSVLFY-UHFFFAOYSA-N 1-(2,4-dinitrophenoxy)-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC=C1OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O WGAXJEXVOSVLFY-UHFFFAOYSA-N 0.000 description 1
QLWKTGDEPLRFAT-UHFFFAOYSA-N 5-Methoxytryptophol Chemical compound COC1=CC=C2NC=C(CCO)C2=C1 QLWKTGDEPLRFAT-UHFFFAOYSA-N 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
KYNSBQPICQTCGU-UHFFFAOYSA-N Benzopyrane Chemical compound C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
208000031636 Body Temperature Changes Diseases 0.000 description 1
206010006242 Breast enlargement Diseases 0.000 description 1
208000022497 Cocaine-Related disease Diseases 0.000 description 1
102000004980 Dopamine D2 Receptors Human genes 0.000 description 1
108090001111 Dopamine D2 Receptors Proteins 0.000 description 1
208000012661 Dyskinesia Diseases 0.000 description 1
208000017701 Endocrine disease Diseases 0.000 description 1
BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
229940123457 Free radical scavenger Drugs 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102000018997 Growth Hormone Human genes 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
206010056438 Growth hormone deficiency Diseases 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
208000004044 Hypesthesia Diseases 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
206010026749 Mania Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
102000016979 Other receptors Human genes 0.000 description 1
208000018238 Primary Headache disease Diseases 0.000 description 1
206010051482 Prostatomegaly Diseases 0.000 description 1
208000001431 Psychomotor Agitation Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
206010038743 Restlessness Diseases 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
208000032140 Sleepiness Diseases 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
208000034972 Sudden Infant Death Diseases 0.000 description 1
206010042440 Sudden infant death syndrome Diseases 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
102000002852 Vasopressins Human genes 0.000 description 1
108010004977 Vasopressins Proteins 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
239000003098 androgen Substances 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000003712 anti-aging effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000002180 anti-stress Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
239000002221 antipyretic Substances 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
230000000949 anxiolytic effect Effects 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
229960002274 atenolol Drugs 0.000 description 1
230000006399 behavior Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000012888 bovine serum Substances 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
201000006145 cocaine dependence Diseases 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
230000002254 contraceptive effect Effects 0.000 description 1
230000002920 convulsive effect Effects 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000012043 crude product Substances 0.000 description 1
XNVMFDGFXSZPDU-UHFFFAOYSA-N cyano nitroformate Chemical compound [O-][N+](=O)C(=O)OC#N XNVMFDGFXSZPDU-UHFFFAOYSA-N 0.000 description 1
230000006735 deficit Effects 0.000 description 1
238000002716 delivery method Methods 0.000 description 1
125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
206010013663 drug dependence Diseases 0.000 description 1
230000001463 effect on reproduction Effects 0.000 description 1
239000003480 eluent Substances 0.000 description 1
230000007368 endocrine function Effects 0.000 description 1
208000030172 endocrine system disease Diseases 0.000 description 1
201000010063 epididymitis Diseases 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
102000015694 estrogen receptors Human genes 0.000 description 1
108010038795 estrogen receptors Proteins 0.000 description 1
230000005284 excitation Effects 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
230000035558 fertility Effects 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
208000031424 hyperprolactinemia Diseases 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
230000000147 hypnotic effect Effects 0.000 description 1
208000034783 hypoesthesia Diseases 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000000509 infertility Diseases 0.000 description 1
230000036512 infertility Effects 0.000 description 1
231100000535 infertility Toxicity 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
230000004410 intraocular pressure Effects 0.000 description 1
230000000366 juvenile effect Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
230000004807 localization Effects 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
239000006210 lotion Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
230000028161 membrane depolarization Effects 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
239000007758 minimum essential medium Substances 0.000 description 1
230000006676 mitochondrial damage Effects 0.000 description 1
IXRLRQDXFMQXPI-UHFFFAOYSA-N n-[2-(2-iodo-5-methoxy-1h-indol-3-yl)ethyl]-2,4-dinitroaniline Chemical compound C12=CC(OC)=CC=C2NC(I)=C1CCNC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O IXRLRQDXFMQXPI-UHFFFAOYSA-N 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
210000003928 nasal cavity Anatomy 0.000 description 1
210000001577 neostriatum Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
239000002547 new drug Substances 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
230000000422 nocturnal effect Effects 0.000 description 1
231100000862 numbness Toxicity 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
230000000247 oncostatic effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
238000006213 oxygenation reaction Methods 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
238000011176 pooling Methods 0.000 description 1
229940124606 potential therapeutic agent Drugs 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
239000002516 radical scavenger Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
230000004799 sedative–hypnotic effect Effects 0.000 description 1
210000004999 sex organ Anatomy 0.000 description 1
208000020685 sleep-wake disease Diseases 0.000 description 1
230000037321 sleepiness Effects 0.000 description 1
239000002002 slurry Substances 0.000 description 1
241000894007 species Species 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
239000002438 stress hormone Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000001360 synchronised effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
150000003568 thioethers Chemical class 0.000 description 1
229930192474 thiophene Natural products 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000003828 vacuum filtration Methods 0.000 description 1
229960003726 vasopressin Drugs 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
229960002555 zidovudine Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Reproductive Health (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Immunology (AREA)
Psychiatry (AREA)
Obesity (AREA)
Psychology (AREA)
Biochemistry (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Toxicology (AREA)
Anesthesiology (AREA)
Gynecology & Obstetrics (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SK404-2003A 2000-10-03 2001-09-25 Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them SK4042003A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IL138825A IL138825A (en)	2000-10-03	2000-10-03	Pharmaceutical preparations containing tryptamine derivatives and similar compounds, and such new compounds
PCT/IL2001/000898 WO2002028347A2 (en)	2000-10-03	2001-09-25	Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them

Publications (1)

Publication Number	Publication Date
SK4042003A3 true SK4042003A3 (en)	2003-09-11

Family

ID=11074694

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK404-2003A SK4042003A3 (en)	2000-10-03	2001-09-25	Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them

Country Status (39)

Country	Link
US (2)	US6780884B2 (de)
EP (1)	EP1331935B1 (de)
JP (1)	JP2004533986A (de)
KR (1)	KR100855385B1 (de)
CN (1)	CN100518735C (de)
AR (1)	AR035587A1 (de)
AT (1)	ATE409474T1 (de)
AU (1)	AU9416201A (de)
BG (1)	BG107759A (de)
BR (1)	BR0114464A (de)
CA (1)	CA2423628C (de)
CL (1)	CL2001002303A1 (de)
CR (1)	CR6968A (de)
CY (1)	CY1110417T1 (de)
CZ (1)	CZ301098B6 (de)
DE (1)	DE60136003D1 (de)
DK (1)	DK1331935T3 (de)
EA (1)	EA005918B1 (de)
EE (1)	EE05192B1 (de)
ES (1)	ES2315307T3 (de)
GT (1)	GT200100197A (de)
HN (1)	HN2001000218A (de)
HU (1)	HU227163B1 (de)
IL (1)	IL138825A (de)
IS (1)	IS2607B (de)
MX (1)	MXPA03002612A (de)
NO (1)	NO20031396L (de)
NZ (1)	NZ525587A (de)
PA (1)	PA8529801A1 (de)
PE (1)	PE20020411A1 (de)
PL (1)	PL365679A1 (de)
PT (1)	PT1331935E (de)
SI (1)	SI1331935T1 (de)
SK (1)	SK4042003A3 (de)
TW (1)	TWI270544B (de)
UA (1)	UA75091C2 (de)
UY (1)	UY26946A1 (de)
WO (1)	WO2002028347A2 (de)
ZA (1)	ZA200303113B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1694323A4 (de) *	2003-12-19	2009-05-13	Elixir Pharmaceuticals Inc	Verfahren zur behandlung einer erkrankung
MXPA06009377A (es) *	2004-02-20	2007-03-07	Lifescape Biosciences Inc	Composiciones y metodos para regulacion del sueno.
AU2006257815A1 (en) *	2005-06-10	2006-12-21	Bipar Sciences, Inc.	PARP modulators and treatment of cancer
US7622495B2 (en) *	2006-10-03	2009-11-24	Neurim Pharmaceuticals (1991) Ltd.	Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
KR101760139B1 (ko)	2007-06-29	2017-07-31	클라렌슈 피티와이 리미티드	안투여를 통한 신경 또는 신경정신 장애의 치료 또는 예방용 약학 조성물
HRP20151367T1 (hr) *	2008-05-13	2016-01-29	Yale University	Kimerne male molekule za pojaäśanje odgovora protutijela na stanice raka
US8852630B2 (en)	2008-05-13	2014-10-07	Yale University	Chimeric small molecules for the recruitment of antibodies to cancer cells
CN103841890B (zh)	2011-05-31	2017-10-27	克拉伦苏股份有限公司	预防和治疗运动相关神经系统疾病的方法
US9073851B2 (en)	2011-10-28	2015-07-07	Board Of Regents, The University Of Texas System	Compositions and methods for treating cancer
CN102816103B (zh) *	2012-08-20	2014-05-07	冉瑞琼	硫化天冬氨酸修饰的退黑素衍生物及其应用
TWI733772B (zh) *	2016-03-14	2021-07-21	美商身體邏輯股份有限公司	用於合成吲哚環核鹼基結合物之組成物及方法
CN116421600B (zh) *	2023-05-29	2024-08-23	重庆医科大学	色醇在制备治疗焦虑的药物中的应用
WO2025137730A1 (en) *	2023-12-22	2025-06-26	Alexander Shulgin Research Institute, Inc.	N-substituted tryptamines and n-substituted lysergamides and their use as therapeutic agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL79264A0 (en) *	1986-06-27	1986-09-30	Univ Ramot	Tryptamine derivatives,pharmaceutical compositions containing them and their use in an assay for melatonin receptors
AUPO274596A0 (en) *	1996-10-04	1996-10-31	Armstrong, Stuart Maxwell	Method for the treatment of neurological or neuropsychiatric disorders
US6310085B1 (en) *	1997-10-03	2001-10-30	Clarencew Pty Ltd.	Method for the treatment of neurological or neuropsychiatric disorders

2000
- 2000-10-03 IL IL138825A patent/IL138825A/en not_active IP Right Cessation
2001
- 2001-09-14 TW TW090122940A patent/TWI270544B/zh not_active IP Right Cessation
- 2001-09-25 CZ CZ20030940A patent/CZ301098B6/cs not_active IP Right Cessation
- 2001-09-25 AU AU9416201A patent/AU9416201A/xx not_active Withdrawn
- 2001-09-25 EE EEP200300135A patent/EE05192B1/xx not_active IP Right Cessation
- 2001-09-25 EA EA200300436A patent/EA005918B1/ru not_active IP Right Cessation
- 2001-09-25 CL CL2001002303A patent/CL2001002303A1/es unknown
- 2001-09-25 WO PCT/IL2001/000898 patent/WO2002028347A2/en not_active Ceased
- 2001-09-25 PL PL01365679A patent/PL365679A1/xx not_active Application Discontinuation
- 2001-09-25 CA CA2423628A patent/CA2423628C/en not_active Expired - Fee Related
- 2001-09-25 HU HU0302616A patent/HU227163B1/hu not_active IP Right Cessation
- 2001-09-25 JP JP2002531973A patent/JP2004533986A/ja active Pending
- 2001-09-25 KR KR1020037004661A patent/KR100855385B1/ko not_active Expired - Fee Related
- 2001-09-25 CN CNB018168043A patent/CN100518735C/zh not_active Expired - Fee Related
- 2001-09-25 ES ES01974651T patent/ES2315307T3/es not_active Expired - Lifetime
- 2001-09-25 DK DK01974651T patent/DK1331935T3/da active
- 2001-09-25 AR ARP010104520A patent/AR035587A1/es unknown
- 2001-09-25 DE DE60136003T patent/DE60136003D1/de not_active Expired - Lifetime
- 2001-09-25 PT PT01974651T patent/PT1331935E/pt unknown
- 2001-09-25 US US10/381,976 patent/US6780884B2/en not_active Expired - Fee Related
- 2001-09-25 SK SK404-2003A patent/SK4042003A3/sk unknown
- 2001-09-25 NZ NZ525587A patent/NZ525587A/en unknown
- 2001-09-25 SI SI200130889T patent/SI1331935T1/sl unknown
- 2001-09-25 BR BR0114464-2A patent/BR0114464A/pt not_active Application Discontinuation
- 2001-09-25 UA UA2003043421A patent/UA75091C2/uk unknown
- 2001-09-25 UY UY26946A patent/UY26946A1/es not_active Application Discontinuation
- 2001-09-25 AT AT01974651T patent/ATE409474T1/de active
- 2001-09-25 EP EP01974651A patent/EP1331935B1/de not_active Expired - Lifetime
- 2001-09-25 MX MXPA03002612A patent/MXPA03002612A/es active IP Right Grant
- 2001-09-26 PE PE2001000960A patent/PE20020411A1/es not_active Application Discontinuation
- 2001-09-27 GT GT200100197A patent/GT200100197A/es unknown
- 2001-10-01 PA PA20018529801A patent/PA8529801A1/es unknown
- 2001-10-02 HN HN2001000218A patent/HN2001000218A/es unknown
2003
- 2003-03-21 IS IS6752A patent/IS2607B/is unknown
- 2003-03-27 NO NO20031396A patent/NO20031396L/no not_active Application Discontinuation
- 2003-04-23 ZA ZA200303113A patent/ZA200303113B/xx unknown
- 2003-04-24 BG BG107759A patent/BG107759A/bg unknown
- 2003-05-02 CR CR6968A patent/CR6968A/es unknown
2004
- 2004-08-20 US US10/921,823 patent/US20050020664A1/en not_active Abandoned
2008
- 2008-12-22 CY CY20081101480T patent/CY1110417T1/el unknown

Also Published As

Publication number	Publication date
UY26946A1 (es)	2001-11-30
ZA200303113B (en)	2004-07-23
CN100518735C (zh)	2009-07-29
NO20031396D0 (no)	2003-03-27
GT200100197A (es)	2002-05-08
EA200300436A1 (ru)	2003-10-30
HU227163B1 (en)	2010-09-28
EE200300135A (et)	2003-08-15
JP2004533986A (ja)	2004-11-11
IS6752A (is)	2003-03-21
CZ301098B6 (cs)	2009-11-04
CA2423628C (en)	2011-04-26
PE20020411A1 (es)	2002-05-16
ES2315307T3 (es)	2009-04-01
US6780884B2 (en)	2004-08-24
HN2001000218A (es)	2002-05-09
KR100855385B1 (ko)	2008-09-04
CA2423628A1 (en)	2002-04-11
US20040029950A1 (en)	2004-02-12
EP1331935B1 (de)	2008-10-01
WO2002028347A2 (en)	2002-04-11
IL138825A0 (en)	2001-10-31
IS2607B (is)	2010-04-15
IL138825A (en)	2006-06-11
WO2002028347A3 (en)	2002-07-04
EP1331935A2 (de)	2003-08-06
NZ525587A (en)	2005-03-24
EE05192B1 (et)	2009-08-17
CZ2003940A3 (cs)	2003-10-15
EA005918B1 (ru)	2005-06-30
DK1331935T3 (da)	2009-02-02
AR035587A1 (es)	2004-06-16
MXPA03002612A (es)	2004-04-02
CN1582147A (zh)	2005-02-16
TWI270544B (en)	2007-01-11
CY1110417T1 (el)	2015-04-29
BR0114464A (pt)	2004-01-20
PL365679A1 (en)	2005-01-10
ATE409474T1 (de)	2008-10-15
AU9416201A (en)	2002-04-15
CL2001002303A1 (es)	2010-06-25
PA8529801A1 (es)	2002-12-30
SI1331935T1 (sl)	2009-04-30
CR6968A (es)	2004-02-25
HUP0302616A2 (hu)	2003-11-28
EP1331935A4 (de)	2004-12-01
KR20030051689A (ko)	2003-06-25
DE60136003D1 (de)	2008-11-13
US20050020664A1 (en)	2005-01-27
BG107759A (bg)	2004-01-30
PT1331935E (pt)	2009-01-19
UA75091C2 (en)	2006-03-15
NO20031396L (no)	2003-03-27
HK1074163A1 (zh)	2005-11-04

Legal Events

Date	Code	Title	Description
2011-08-04	FD9A	Suspended procedure due to non-payment of fee

Publication	Publication Date	Title
US6780884B2 (en)	2004-08-24	Derivating of tryptamine and analogous compounds and pharmaceutical formulations containing them
TWI285634B (en)	2007-08-21	Indole derivatives
AU2001294162B2 (en)	2007-09-27	Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them
AU2001294162A2 (en)	2003-07-24	Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them
AU2001294162A1 (en)	2002-06-27	Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them
HK1074163B (en)	2010-04-09	Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them